Trial · NCT07132983
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ensifentrine single dose area under the curve from time 0 to time t (AUC0-t) | Day 1 through 48 hours after each dose of study medication | |
| Primary | Ensifentrine single dose area under the curve from time 0 extrapolated to infinity (AUC0-inf) | Day 1 through 48 hours after each dose of study medication | |
| Primary | Ensifentrine single dose maximum observed concentration (Cmax) | Day 1 through 48 hours after each dose of study medication | |
| Primary | Glycopyrronium single dose AUC0-t | Day 1 through 48 hours after each dose of study medication | |
| Primary | Glycopyrronium single dose AUC0-inf | Day 1 through 48 hours after each dose of study medication | |
| Primary | Glycopyrronium single dose Cmax | Day 1 through 48 hours after each dose of study medication | |
| Primary | Change from average baseline in forced expiratory volume over 1 second (FEV1) to FEV1 area under the curve versus time from time 0 to 12 hours (AUC0-12h) | Baseline through 12 hours after each dose of study medication | |
| Primary | Change from average baseline FEV1 to average FEV1 area under the curve versus time from time 0 to 4 hours (AUC0-4h) | Baseline through 4 hours after each dose of study medication | |
| Primary | Change from average baseline FEV1 to peak FEV1 measured over 4 hours post-dose | Baseline through 4 hours after each dose of study medication | |
| Primary | Change from average baseline FEV1 to 12-hour post-dose (evening trough) FEV1 | Baseline through 12 hours after each dose of study medication | |
| Primary | Incidence of treatment emergent adverse events (TEAEs) | From first dose through the end of study (approximately 6 weeks) | |
| Primary | Change from baseline in QTcF as measured by 12-lead ECG | Baseline and visits 2, 5, 8, 11, and 14 | |
| Primary | Change from baseline in blood pressure | Baseline through end of study (approximately 6 weeks) | |
| Primary | Change from baseline in heart rate | Baseline through end of study (approximately 6 weeks) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07132983/registered